Manuscripts (Published)
Bai RY, Staedtke V, Xuwei X, Riggins GJ. Prevention of tumor seeding during needle biopsy by chemotherapeutic-releasing gelatin sticks. Oncotarget. 2017 Feb; 8(16): 25955-25962.
Bornhorst M, Hwang EI. Experimental Therapeutic Trial Design for Pediatric Brain Tumors. J Child Neurol. 2016 Oct; 31(12):1421-32.
Brock EJ, Ji K, Reiners JJ Jr. & Mattingly RR. How to target activated Ras proteins: Direct inhibition vs. induced mislocalization. Mini Rev Med Chem. 2016; 16(5): 358–369.
Choi K, Komurov K, Fletcher JS, Jousma E, Cancelas JA , Wu J, Ratner N. An inflammatory gene signature distinguishes neurofibroma SC and macrophages from cells in the normal peripheral nervous system. Nature. 2017 March 3.
de Blank P, Cole K, Kersun L, Green A, Wilkes JJ, Belasco J, Bagatell R, Bailey LC, Fisher MJ. FDG-PET in two cases of neurofibromatosis type 1 and atypical malignancies. Curr Oncol. 2014 Apr; 21(2):e345-8.
de Blank P, Ellika S, Kader M, Fisher MJ. Advanced Imaging in Optic Pathway Gliomas. Journal of Pediatric Neuroradiology 2015; 4(4):132-144.
de Blank P*, Ostrom QT*, Rouse C, Wolinsky Y, Kruchko C, Salcido J, Barnholtz-Sloan JS. Years of Life Lived with Disease and Years of Potential Life Lost Due to Cancer in Children <20 Years Old in the United States. Cancer Medicine 2015 ,4(4):608-19. *co-first authors.
de Blank P, Berman JI, Fisher MJ. Systemic Chemotherapy and White Matter Integrity in Tracts Associated with Cognition Among Children with Neurofibromatosis Type 1. Pediatric Blood & Cancer. 2016 May; 63(5):818-24.
de Blank PM, Fisher MJ, Lu L, Leisenring WM, Ness KK, Sklar CA, Stovall M, Vukadinovich C, Robison LL, Armstrong GT, Krull KR. Impact of Vision Loss Among Survivors of Childhood Central Nervous System Astroglial Tumors. Cancer. 2016 Mar; 122(5):730-9.
de Blank P, Fisher MJ, Gittleman H, Barnholtz-Sloan JS, Badve C, Berman JI. Validation of an Automated Tractography Method for the Optic Radiations as a Biomarker of Visual Acuity in Neurofibromatosis-Associated Optic Pathway Glioma. Experimental Neurology, 2017 Jun 3 epub ahead of print. PMID 28587872.
de Blank P, Fisher MJ, Liu GT, Gutmann DH, Listernick R, Ferner RE, Avery RA. Optic Pathway Gliomas in Neurofibromatosis Type 1 – An Update: Surveillance, Treatment Indications, and Biomarkers of Vision. Journal of Neuro-Ophthalmology 2017, 37 (Suppl 1): S23-S32.2017
Dombi E, Baldwin A, Marcus LJ, Fisher MJ, Weiss B, Kim A, Whitcomb P, Martin S, Aschbacher-Smith LE, Rizvi TA, Wu J, Ershler R, Wolters P, Therrien J, Glod, J, Belasco JB, Schorry E, Brofferio A, Starosta AJ, Gillespie A, Doyle AL, Ratner N, Widemann BC. Activity of Selumetinib in NeurofibromatosisType 1–Related Plexiform Neurofibromas. N Engl J Med 2016 Dec; 375(26); 2550-60.
Draucker CB, Nutakki K, Varni JW, Swigonski NL. The health-related quality of life of children, adolescents, and young adults with neurofibromatosis type 1 and their families: Analysis of narratives. J Spec Pediatr Nurs. 2017 Feb 15.
Ferguson MJ, Rhodes SD, Jiang L, Li X, Yuan J, Yang X, Zhang S, Vakili ST, Territo P, Hutchins G, Yang FC, Ingram DA, Clapp DW, Chen S. Preclinical evidence for the use of sunitinib malate in the treatment of plexiform neurofibromas. Pediatr Blood Cancer 2016;63: 206–213.
Hanemann CO, Blakeley JO, Nunes FP, Robertson K, Stemmer-Rachamimov A, Mautner V, Kurtz A, Ferguson M, Widemann BC, Evans DG, Ferner R, Carroll SL, Korf B, Wolkenstein P, Knight P, Plotkin SR; REiNS International Collaboration. Current status and recommendations for biomarkers and biobanking in neurofibromatosis. Neurology. 2016 Aug 16;87(7 Suppl 1):S40-8.
Jones DTW, Kieran MW, Bouffet E, Alexandrescu S, Bandopadhayay P, Bornhorst M, Ellison D, Fangusaro J, Fisher MI, Foreman N, Fouladi M, Hargrave D, Hawkins C, Jabado N, Massimino M, Mueller S, Perilongo G, Schouten-van Meeteren AYN, Tabori U, Warren K, Waanders AJ, Walker D, Weiss W, Witt O, Wright K, Zhu Y, Bowers DC, Pfister SM, Packer RJ. Pediatric Low-Grade Gliomas: Next Biologically Driven Steps. Neuro Oncol. 2017 Aug 2, PMID: 29016845
Kraniak JM, Chalasani A, Wallace MR, Mattingly RR. Development of 3D culture models of plexiform neurofibroma and initial application for phenotypic characterization and drug screening. Exp Neurol. 2017 Oct 18
Kraniak JM, Mattingly RR, Sloane BF (2018). Roles of pericellular proteases in tumor angiogenesis: therapeutic implications, ch14, in Non-kinase Receptor Tyrosine Kinase Inhibitors: A New Therapeutic Approach in Metastatic Cancer. Janetka J (Ed). Wiley, ISBN: 9781119300182
Lai JS., Jensen SE, Patel Z, Listernick R, Charrow, J. Using a qualitative approach to conceptualize concerns of patients with neurofibromatosis Type 1 associated plexiform neurofibromas (pNF) across the lifespan. American Journal of Medical Genetics Part A. 2017 173(1), 79-87.
Li H, Chang LJ, Neubauer D, Muir D, Wallace MR, Immortalization of human normal and NF1 neurofibroma schwann cells. Laboratory Investigation 2016 Oct; 96:1105–1115.
Nutakki K, Varni JW, Steinbrenner S, Draucker CB, Swigonski NL. Development of the pediatric quality of life inventory neurofibromatosis type 1 module items for children, adolescents and young adults: qualitative methods. J Neurooncol. 2017 Mar, 132: 135-143.
Packer RJ, Pfister S, Bouffet E, Avery R, Bandopadhayay P, Bornhorst M, Bowers DC, Ellison D, Fangusaro J, Foreman N, Fouladi M, Gajjar A, Haas-Kogan D, Hawkins C, Ho CY, Hwang E, Jabado N, Kilburn LB, Lassaletta A, Ligon KL, Massimino M, Meeteren SV, Mueller S, Nicolaides T, Perilongo G, Tabori U, Vezina G, Warren K, Witt O, Zhu Y, Jones DT, Kieran M. Pediatric low-grade gliomas: implications of the biologic era. Neuro Oncol. 2016 Sep 28.
Patel ZS, Jensen SE, Lai JS. Considerations for conducting qualitative research with pediatric patients for the purpose of PRO development. Quality of Life Research, 2016; 25, 2193-2199.
Roberts NJ, Zhang L, Janku F, Collins A, Bai RY, Staedtke V, et al. Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses. Sci Transl Med. 2014; 6(249): 249ra111.
Staedtke V, Bai RY, Laterra JJ. Investigational new drugs for brain cancer. Expert Opin Investig Drugs. 2016 Aug; 25(8):937-56.
Staedtke V, Roberts NJ, Bai RY, Zhou S. Clostridium novyi-NT in cancer therapy. Journal for Genes and Disease. 2016 June; 3(2):144–152
Staedtke V, Bai RY, Blakeley JO. Cancer of the peripheral nerve in neurofibromatosis Type 1. (Review). Neurotherapeutics. 2017, 14: 298-306.
Walsh KS, Janusz J, Wolter PL, Martin S, Klein-Tasman, Toledo-Tamula A, Thompson HL, Payne JM, Hardy KK, de Blank P, Semerjian C, Gray LS, Solomon SE, Ullrich N, for the REiNS International Collaboration. Neurocognitive outcomes in neurofibromatosis clinical trials: Recommendations for the domain of attention. Neurology. 2016 August 16; 87(7 Suppl 1): S21-30.
Wolters PL, Martin S, Merker VL, Tonsgard JH, Solomon SE, Baldwin A, Bergner AL, Walsh K, Thompson HL, Gardner KL, Hingtgen CM, Schorry E, Dudley WN, Franklin B; REiNS International Collaboration. Patient-reported outcomes of pain and physical functioning in neurofibromatosis clinical trials. Neurology. 2016 Aug 16;87(7 Suppl 1):S4-S12.
Manuscripts (In Press)
de Blank P, Coffey M, Fisher M. Neuro-Oncologic Considerations in Pediatric Oculoplastic Surgery in Pediatric Oculoplastic Surgery, 2nd edition. J Katowitz & W Katowitz, eds. New York, NY. Springer-Verlag. In press.
Manuscripts (Submitted)
Blakeley JO, Wolkenstein P, Widemann BC, Lee J, Le LQ, , Jackson, R, Stathis, M, Verma S. Creating a Comprehensive Research Strategy for Cutaneous Neurofibromas. Submitted to Neurology.
Brosseau JP, Pichard DC, Legius E, Wolkenstein P, Lavker RM, Blakeley JO, Riccardi VM, Verma S, Brownell I, Le LQ. The Biology of Cutaneous Neurofibromas Submitted to Neurology.
Cannon, A, Jarnagin, K, Korf, B, Widemann, BC, Casey, DC, Ko, HS, Blakeley, JO, Verma, S, Pichard, DC. Clinical Trial Design for Cutaneous Neurofibromas. Submitted to Neurology.
Cannon A, Chen MJ, Li P, Boyd KP, Theos A, Redden DT, Korf B. Cutaneous neurofibromas in neurofibromatosis type 1: a quantitative natural history study. Submitted to Neurology
Carrió M, Gel B, Terribas E, Zuquiatti AC, Moliné T, Rosas I, Teulé A, Ramon y Cajal S, López-Gutiérrez JC, Blanco I, Castellanos E, Lázaro C, Stemmer-Rachamimov A, Romagosa C, Serra E. Analysis of intra-tumor heterogeneity in Neurofibromatosis Type 1 plexiform neurofibromas and neurofibromas with atypical features: correlating histological and genomic findings. Submitted to Human Mutation
Allen, T., Struemph, K., Toledo-Tamula, M.A., Wolters, P., Baldwin, A., Widemann, B., & Martin, S. The Relationship between Heart Rate Variability, Psychological Flexibility, and Pain in Neurofibromatosis Type 1. Submitted to the Journal of Contextual Behavioral Science.
de Blank P, et al. Clinical Endpoints for Attention and Executive Function in NF1 Trials: A report from the REiNS NeuroCognitive Committee. Submitted to Neurology.
Ferrer, M, Gosline, S, Stathis, M, Zhang, X, Guo, X, Guha, R, Ryman, DA, Wallace, MR, Kasch-Semenza, L, Hao, H, Ashworth, R, Ling, H, Thomas, C, Verma, S, Guinney, J, Blakeley, JO. Pharmacological profiling and genomic characterization of human derived neurofibromatosis type 1 plexiform neurofibroma-derived schwann cells. Submitted to Scientific Data
Gross A, Akshintala V, Baldwin A, Dombi E, Ukwuani S, Goodwin A, Lieweher D, Steinberg S, Widemann B. Association of clinical morbidities and plexiform neurofibroma volume changes in neurofibromatosis type 1. Submitted to American Society of Pediatric Hematology/Oncology.
Heaney A, Wilburn J, McKenna SP, Huson S, Blakeley J, Langmead S. A qualitative study of the impact of Plexiform Neurofibromas on need fulfillment in adults with Neurofibromatosis Type 1. Submitted to Journal of Clinical Nursing.
Jensen SE, Patel, ZS, Listernick, R., Charrow, J, Lai, J-S. Symptoms Experienced by Patients with Neurofibromatosis Type 1 Associated Plexiform Neurofibromas from Childhood into Adulthood.
Ortonne,N, Wolkenstein, P, Blakeley, JO, Korf,B, Plotkin, S, Riccardi, VM, Miller, DC, Huson S, Peltonen, J, Rosenberg, A, Carroll, SL, Verma, S, Mautner, V, Upadhyaya, M, Stemmer-Rachamimov, A. Cutaneous Neurofibromas: Current Clinical and Pathological Issues. Submitted to Neurology.
Steensma M. Enhanced MET signaling drives malignant tumorigenesis in a mouse model of Neurofibromatosis Type 1. Submitted to JCI.
Strafstrom C, Staedtke V, Comi AM. Epilepsy mechanisms in neurocutaneous disorders. (Review)— Submitted to Frontiers in Neurology.
Verma, S, Riccardi, VM, Plotkin, SR, Weinberg, Anderson, RR, Blakeley, JO, Jarnagin, K, Lee, J. Considerations for Development of Therapies for Cutaneous Neurofibroma. Submitted to Neurology.
Manuscripts (In Preparation)
Bornhorst M, et al, Establishment and Characterization of a Clinically Relevent PDX model of Childhood Low Grade Glioma.
Bornhorst M, et al, Short Term Mek-Inhibitor Treatment Prevents Optic Nerve Glia Pathology in an Nf1-deficient Mouse.
Carrió M, Richaud Y, Gel B, Terribas E, Jimenez-Delgado S, Rosas I, Mazuelas H, Biayna J, Vendredy L, Castellanos E, Blanco I; Lázaro C, Raya A, Serra E, Generation of a collection of plexiform neurofibroma-derived iPSCs from Neurofibromatosis Type 1 cancer syndrome patients carrying naturally occurring tumor mutations.
de Blank P, Simmons I, Sehested A, Fisher MJ. Low Grade Glioma Presenting in the Optic Pathways and Hypothalamus (NF1 and Sporadic)” in Brain and Spinal Tumors of Childhood, 2nd edition. David A. Walker, Giorgio Perilongo, Roger E. Taylor and Ian F. Pollack, eds. London, UK. Taylor & Francis.
Fisher MJ, Belzberg A, de Blank P, De Raedt T, Elefteriou F, Ferner R, Giovannini M, Harris GJ, Kalamarides M, Karajannis M, Kim A, Lázaro C, Le LQ, Li W, Listernick R, Martin S, Morrison H, Pasmant E, Ratner N, Schorry E, Ullrich N, Viskochil D, Weiss B, Widemann B, Zhu Y, Serra E. 2016 CTF Conference on Neurofibromatosis Type 1, Neurofibromatosis Type 2 and Schwannomatosis. (For submission to the American Journal of Medical Genetics)
de Blank P, Ma D, Badve C, Pahwa S, Dastmalchian S, Stearns D, Rukin Gold D, Tomei K, Barnholtz-Sloan JS, Sloan A, Gulani V, Griswold M. Using MR Fingerprinting in Pediatric and AYA Brain Tumors.
de Blank P, Ma D, Badve C, Pahwa S, Dastmalchian S, Stearns D, Rukin Gold D, Tomei K, Barnholtz-Sloan JS, Sloan A, Gulani V, Griswold M. Using MRF to Characterize NF1Associated Signal Abnormalities.
Nutakki K, Varni JW, Swigonski NL. Health-Related Quality of Life in Children, Adolescents and Young Adults with Neurofibromatosis Type 1: A Multisite National Study. In process of submission to Journal of Pediatrics.
Presentations
Allen et al. “Psychophysiological correlates of pain in NF1: The role of heart rate variability and psychological flexibility.” Children’s Tumor Foundation Conference, Washington, DC, June 2017. Poster presentation.
Aschbacher-Smith L, Ratner N, et al. “Simultaneous Inhibition of the MAPK and STAT3 Signaling Pathways Demonstrates Efficiacy in a Preclinical Mouse Model of Neurofibromatosis Type.” Children’s Tumor Foundation Conference, Austin, TX, June 2016. Poster presentation.
Blankstein L, et al. “Clinical drug development – from the bench to patients.” Francis Collin Scholars Orientation, Washington, DC, June 2017. Oral presentation
Bornhorst M, “Short Term Mek-inhibitor Treatment Prevents Optic Nerve Glia Pathology in an Nf1-deficient Mouse Model.” Pediatric Society for NeuroOncology-Oral presentation, June 16, 2017; European Neurofibromatosis Conference, September 2016, oral presentation; Children’s Tumor Foundation Conference, Austin TX, June 2016. Oral presentation; International Society for Pediatric Neuro-Oncology, June 2016. Oral presentation; The Hospital for Sick Children, April 2016, Oral presentation.
Bornhorst M, Jecrois E, Mugayo D, Zhu Y, “The role of Mek-inhibitors for the prevention and treatment of optic pathway gliomas in a Nf1 deficient mouse model.” Children’s Tumor Foundation Conference, Washington, DC June 2017; Child Neurology Society Conference, October 2016. Poster presentation.
Bornhorst M, et al. “Preventative MEK-i therapy in NF1.” Francis Collin Scholars Orientation, Washington, DC, June 2017. Oral presentation.
Bornhorst M, “Targeted Therapy for the Treatment and Prevention of Low Grade Gliomas.” University of Michigan Research Seminar, October 4, 2017. Invited speaker.
Bornhorst M, “Targeted Therapy for the Prevention of NF1-Associated Optic Pathway Gliomas.” NCI Pediatric Oncology Branch Research Meeting, October 19, 2017. Invited speaker.
Burks, C, Rhodes, S, Bessler, W, Smith, A, Gelhausen, J, Jones, DR, Blakeley, JO, Clapp DW. The impact of mast cell stabilization with ketotifen in preventing NF1 plexiform neurofibroma tumorigenesis. Children’s Tumor Foundation Conference, Washington D.C., June 2017. Poster presentation.
Cannon A, Chen MJ, Theos A, Korf B, “Longitudinal Natural History Study of Dermal Neurofibromas.” Children’s Tumor Foundation Conference, Austin TX, June 2016. Poster presentation.
Cannon A, et al. “Cutaneous Neurofibromas in NF1: A quantitative Natural History Study.” Children’s Tumor Foundation Conference, Washington, DC, June 2017. Poster presentation.
Cannon A, “Cutaneous neurofibromas in NF1: a quantitative natural history study.” Francis Collins Scholars Orientation, Washington, DC, June 2017. Oral presentation.
Casey D. “Regulatory Considerations and Drug Development.” Francis Collins Scholars Orientation, Washington, DC, June 2017. Oral presentations.
Carrió M, Terribas, E, Gel B, Flamerich C, Moliné T, Rosas, I, Castellanos E, Blanco I, Lázaro C, Serra A. “Exploring intra–‐tumor heterogeneity in Neurofibromatosis Type 1 plexiform neurofibromas: integration of histological and genomic data reveals correlation between progressive loss of CDKN2A and degree of cellular atypia.” United States and Canadian Academy of Pathology 2016 Meeting, Seattle, WA. Oral presentation.
Carrió M, Richaud Y, Gel B, Castellanos E Terribas, E, Rosas, I, Biayna J, Blanco I, Lázaro C, Raya Á, Serra A. “Generation of patient-specific NF1(+/-) and NF1(-/-) induced pluripotent stem cells (iPSC) derived from plexiform neurofibromas. Differentiation towards neural crest and SC.” 17th European NF Meeting, Padova, Italy. September 8-11, 2016. Poster presentation.
Choi K, Wu J, Ratner N, et al. “An Inflammatory Gene Signature Distinguishes Neurofibroma Schwann Cells and Macrophages From Their Counterparts in the Normal Peripheral Nervous System.” Children’s Tumor Foundation Conference, Austin, TX, June 2016. Poster presentation.
Clapp DW. “Development of new therapies for NF1 and NF2: Strategy for orphan diseases.” Children’s Tumor Foundation Conference, Washington, DC, June 2017. Oral presentation.
Clapp DW. “Identification of Therapies for Plexiform Neurofibromas.” Francis Collins Scholars Orientation, Washington, DC June 2017. Oral presentation.
de Blank P. “Radiographic Biomarkers in NF1-Associated Brain Tumors,” Neurofibromatosis Symposium, Van Andel Research Institute, Spectrum Health/Helen DeVos Children’s Hospital Michigan State University College of Human Medicine, Grand Rapids, MI, April 2015. Oral presentation.
de Blank P, Fisher MJ, Lu L, Leisenring WM, Ness KK, Sklar CA, Stovall M, Vukadinovich C, Robison LL, Armstong GT, Krull KR. “The Impact of Vision Loss Among Survivors of Childhood Central Nervous System Astroglial Tumors.” Children’s Tumor Foundation Conference, Monterrey CA, June 2015. Oral presentation.
de Blank, Berman JI, Roberts TPL, Fisher MJ. “The Effect of Systemic Chemotherapy on Cognitive Tracts in NF1.” Children’s Tumor Foundation Conference, Monterrey CA, June 2015. Poster presentation.
de Blank P, Fisher MJ, Roberts TPL, Berman JI. “The Effect of Systemic Chemotherapy on White Matter Tracts Involved with Cognition in Children with NF1-Associated Optic Pathway Gliomas.” 2015 Annual Meeting of the International Society for Magnetic Resonance in Medicine, Toronto, Canada, May 2015. Oral Presentation.
de Blank P. “Investigating NF1 with Novel Imaging: Measuring Tumor and Function” Cincinnati Children’s Research Foundation, Cincinnati, OH, February 2016. Special seminar.
de Blank P. “Quantitative Imaging in Pediatric Brain Tumors: Biomarkers of Diagnosis, Prognosis and Function.” University of California, San Francisco, San Francisco, CA, February 2016. Special Seminar.
de Blank P. “MRI in Pediatric Brain Tumors: Improving Assessment and Outcomes.” Stanford University, Stanford, CA, March 2016. Special Seminar.
de Blank P. “Getting More from your MRI: Quantitative Tools in Pediatric Brain Tumors.” Rainbow Babies & Children’s Hospital, Cleveland, OH, May 2016. Pediatric Grand Rounds.
de Blank P. “Clinical Management of Optic Pathway Gliomas in NF1. Educational Symposium: Low Grade Glioma.” Children’s Tumor Foundation annual meeting, Austin TX, June 2016. Oral presentation.
de Blank P. “All NF patients should undergo whole body MRI at diagnosis: a criticism.” Children’s Tumor Foundation annual meeting, Austin TX, June 2016. Oral presentation.
de Blank P, Ma D, Badve C, Rukin Gold D, Gulani V, Griswold M. “Characterization of Brain Tumors and Spongiotic Change using Magnetic Resonance Fingerprinting: Initial Experience.” Children’s Tumor Foundation annual meeting, Austin TX, June 2016. Oral presentation.
de Blank P. “The Role of Quantitative MRI in Pediatric Brain Tumors.” The Hospital for Sick Children, Toronto, Ontario, Canada, January 14, 2016. NeuroOncology Divisional Grand Rounds.
de Blank P, Badve C, Ma D, Pahwa S, Yang S, Dastmalchian S, Stearns D, Gulani V, Griswold M. “Characterization of Tumor Grade and Extent Using Magnetic Resonance Fingerprinting: Initial Results.” International Society for Pediatric Neuro-Oncology annual meeting, Liverpool, UK, June 2016. Oral presentation.
de Blank P, et al. “Effect of Age and Neurofibromatosis Type 1 status on white matter integrity in the optic radiations in children.” Children’s Tumor Foundation Conference, Washington, DC, June 2017.Poster presentation.
de Blank P, et al. “Using DTI to Investigate NF1.” Francis Collin Scholars Orientation, Washington, DC, June 2017. Oral presentation.
Eulo V, Shern JF, Stewart DR, Miller D, Landeau M, Widemann BC, Gutmann DH, and Hirbe AC. “Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors.” Connective Tissue Oncology Society Meeting, Maui, HI, November 2017. Poster presentation.
Godec A, Kaushal M, Zhang X, and Hirbe A. “Whole Exome Sequencing Reveals the Order of Genetic Changes during Metastasis in Two Individuals.” Connective Tissue Oncology Society Meeting, Maui, HI, November 2017. Poster presentation.
Gross A. “NF1 natural history: Morbidity analysis.” REiNS Winter Meeting, December 7, 2015. Oral presentation.
Korf B, “Towards Genome-Guided Therapy for NF1.” Children’s Tumor Foundation Conference, Washington, DC, June 2017. Oral presentation.
Lai, JS, Beaumont, J, Jensen, SE. “Quality of life for patients with neurofibromatosis type 1 associated plexiform neurofibromas (pNF).” ISPOR 20th Annual European Congress, November 4-8, 2017, Glasgow, Scotland. Poster presentation. Award for best poster presentation finalist.
Martin S, et al. “Acceptance and commitment training for adolescents and young adults with NF1, plexiform neurofibromas, and chronic pain: preliminary results from a randomized controlled trial.” Children’s Tumor Foundation Conference, Washington, DC, June 2017. Poster presentation.
Martin S. et al. “Psychophysiological correlates of pain in NF1: The role of heart rate variability and psychological flexibility.” Children’s Tumor Foundation Conference, Washington DC, June 2017. Poster presentation. AWARDED TOP PRIZE
Mattingly RR and Kraniak JM. “Development of 3D Organotypic Models of Human NF1 Plexiform Neurofibromas for Drug Screening.” Children’s Tumor Foundation Conference, Monterrey, CA, June 2015. Poster presentation.
Mattingly RR, “Spatio-Temporal Modeling and Live-Cell Imaging of 3D Tumor Microenvironment in TAME Chambers.” Physical Sciences Oncology Center at Moffitt Cancer Center, 2015. Oral presentation.
McKenna SP, Twiss JT, Wilburn, J, Huson S, Blakeley J. “Measuring needs-based quality of life in adults with Neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (pNFs).” Children’s Tumor Foundation Conference, Monterrey, CA, June 2015. Poster presentation.
Nutakki K, Swigonski N, et al. “Development of the pediatric quality of life inventoryTM neurofibromatosis type 1 module for children and young adults: Qualitative methods.” Children’s Tumor Foundation Conference, Monterrey, CA, June 2015. Poster presentation.
Rasola A, “Shutting your TRAP to kill Neurofibromas? The oncogenic role of the mitochondrial chaperone TRAP1 in NF1.” Children’s Tumor Foundation Conference, Washington, DC, June 2017. Oral presentation.
Rasola A, et al. “TRAPping the metabolic adaptations of NF1-associated tumors.” Children’s Tumor Foundation Conference, Washington, DC, June 2017, Poster presentation.
Ratner N, “NF Mouse Models.” Children’s Tumor Foundation Conference, Washington, DC, June 2017. Oral presentation.
Serra E, “Generation of patient-specific NF1(+/-) and NF1(-/-) induced pluripotent stem cells (iPSC) derived from plexiform neurofibromas. Genomic characterization and differentiation capacity.” Children’s Tumor Foundation Conference, Monterrey, CA, June 2015. Oral presentation.
Serra E, Differentiation of plexiform neurofibroma (PNF)-derived NF1(+/-) and NF1 (-/-) iPS cells into Schwann cells mimicking primary PNF cells: closing the circle. 11 NF1 Workshop, September 2016, Leuven, Belgium. Oral presentation
Serra E, “Differentiation of Plexiform Neurofibroma (pNF)-derived NF (+/-) and NF1 (-/-) iPS cells into Schwann Cells Mimicking Primary pNF cells: Closing the Circle.” Children’s Tumor Foundation Conference, Washington, DC, June 2017. Oral presentation.
Springer M, Jousma E, Wu J, Choi K, Rizvi TA, Ratner N. “RNASeq Identification of Potential Mediators of Neurofibroma Growth and Resistance to Therapy.” Children’s Tumor Foundation Conference, Monterrey, CA, June 2015, Oral presentation.
Staedtke V, Bai RY, Roberts NJ, Vogelstein B, Zhou S. “Clostridium novyi-NT can cause tumor regressions in malignant peripheral nerve sheath tumors across species.” Children’s Tumor Foundation Conference, Monterrey, CA, June 2015. Oral presentation.
Staedtke V, Bai RY, Roberts NJ, Vogelstein B, Zhou S. Clostridium novyi-NT can cause tumor regressions in malignant peripheral nerve sheath tumors across species. Children’s Tumor Foundation Conference, Austin, TX, June 2016. Oral presentation.
Staedtke V, “Development of a novel treatment approach to Neurofibromatosis Type 1-related MPNST using genetically engineered Clostridium novyi-NT.” Francis Collins Scholars Orientation, Washington, DC, June 2017. Oral presentation.
Staedtke V, “Development of a novel treatment approach to cancer using clostridium novyi-nt. Indiana University, November 2017. Oral presentation.
Steensma M, “Tumorigenesis in NF1: Environmental Factors, Screening, and Treatment Update.” What’s new in treatment and Research for Neurofibromatosis Conference, University of Michigan Health System, Ann Arbor, MI, April 2016. Oral presentation.
Steensma M, et al. “Genomic Alterations Modulate MET-dependency in murine MPNSTs.” Children’s Tumor Foundation Conference, Austin, TX, June 2016. Poster presentation.
Steensma M, et al. “Investigating RAS and RTK signaling in MPNST progression and drug resistance.” Children’s Tumor Foundation Conference, Washington, DC, June 2017. Poster presentation.
Steensma M, et al. “Development of new therapies for NF1 and NF2: Strategy for orphan diseases.” Children’s Tumor Foundation Conference, Washington, DC, June 2017. Poster presentation.
Steensma M, “Exploiting therapeutic vulnerabilities in NF1-related peripheral nerve tumors.” Francis Collins Scholars Orientation, Washington, DC, June 2017. Oral presentation.
Struemph K, Baldwin A, Widemann B, Martin S, Wolters P. “Patient reported outcome development for patients with NF1 and Plexiform neurofibromas; Qualitative evaluation of existing measures of pain.” REiNS Winter Meeting, December 7, 2015, Oral presentation.
Struemph K, et al. “Development of Patient-report outcomes (PROs) to assess pain in individuals with neurofibromatosis 1 (NF1) and plexiform neurofibromas (PNs) for clinical trial endpoints: results from adult participants.” Children’s Tumor Foundation Conference, Washington, DC, June 2017. Poster presentation.
Struemph, K.L., Allen T.M., Tamula, M.A., Wolters, P., Widemann, B., and Martin, S. Good Things Come in Small Packages: Improvements in Depression and Pain Related Anxiety Following a Brief Mixed-Methods Acceptance and Commitment Training (ACT) Intervention. Mid Atlantic Chapter Association for Contextual and Behavioral Sciences Conference, October 2017, Arlington, VA. Poster presentation.
Swigonski N, et al. “Health-related quality of life in children, adolescents, and young adults with neurofibromatosis type 1: a multisite national study.” Children’s Tumor Foundation Conference, Washington, DC, June 2017. Poster presentation.
Swigonski N et al. “PedsQL Neurofibromatosis type 1 module for children, adolescents, and young adults: feasibility, reliability, and validity.” Children’s Tumor Foundation Conference, Washington, DC, June 2017. Poster presentation.
Tavares E, Tuskan R, Lee M-H, Jones G, and Reilly K. “Development of a novel plexiform neurofibroma farming system for 96-well plate drug screening.” Children’s Tumor Foundation Conference, Monterrey, CA, June 2015. Poster presentation.
Verma S, Wolkenstein P, Le LQ, et al “Establishing a Roadmap for Therapies Development for Cutaneous Neurofibromas.” Society of Investigative Dermatology National Meeting, Portland, Oregon, April 2017. Poster presentation.
Verma S. “Drug Discovery and Development: Looking Beyond the Surface.” GTC European Pharma Summit, November 2017, Berlin, Germany. Oral Presentation (Closing plenary).
Wallace P, et al. “Genomic Characterization of Immortalized NF1 Schwann Cells.” Children’s Tumor Foundation Conference, Austin, TX, June 2016. Poster presentation.
Wolkenstein P, Blakeley JO, “Defining Cutaneous Neurofibromas.” Children’s Tumor Foundation Conference, Washington, DC, June 2017. Oral presentation.
Wolters, P., Struemph, K., Martin, S., Tonsgard, J., MacKenzie, C., Schorry, E., Manning, S., Walsh, K., Kennedy, T., & Widemann, B. “Development of Patient-reported Outcomes (PROs) to Assess Pain in Individuals with Neurofibromatosis (NF1) and Plexiform Neurofibromas (PNs) for Clinical Trial Endpoints: Preliminary Data from Qualitative Research.” Children’s Tumor Foundation Conference, Austin, TX, June 2016. Poster presentation.
Wolters P, et al. “Using patient-reported outcomes (PROs) to assess pain and classify pain morbidity in neurofibromatosis 1 (NF1) clinical trials for plexiform neurofibromas (PNs): Baseline data from the pediatric phase II Selumetinib trial.” Children’s Tumor Foundation Conference, Washington, DC June 2017. Poster presentation.
Zhang X, Eulo V, Godec A, Dahiya S, and Hirbe AC. “ßIII-spectrin staining as a biomarker for diagnosis of MPNST.” Connective Tissue Oncology Society Meeting, Maui, HI, November 2017. Poster presentation.